Form 0920-0978 2023 LABORATORY TESTING PRACTICES FOR CANDIDEMIA QUESTIO

[NCEZID] Emerging Infections Program

Att19_HAIC_2023 Laboratory Survey Candidemia

HAIC Candidemia Periodic Laboratory Survey

OMB: 0920-0978

Document [pdf]
Download: pdf | pdf
Lab ID No. [][][][][][]
2023 LABORATORY TESTING PRACTICES FOR CANDIDEMIA QUESTIONNAIRE
1) What kind of laboratory is this? (select one)
Hospital laboratory
Commercial laboratory (Quest, etc.)

Other (specify) ______________________
Unknown

2) Does this laboratory ever receive blood cultures from nursing homes or other long term care facilities?
Yes
No
Unknown
3) Does the clinical microbiology laboratory at your institution have a separate Mycology section or laboratory?
Yes
No
Unknown
4) What kind of blood culture system does your laboratory use? (check all that apply)
BacT/Alert
Bactec FX
BacT/Alert 3D
Isolator tubes
VersaTREK
Other (specify) ______________________
Bactec 9240
5) What is the approximate volume of fungal cultures ordered and performed annually in your laboratory for
any specimen type?
Specify number: ______________
Unknown
6) What is the approximate volume of fungal blood cultures ordered andperformed annually in your
laboratory?
Specify number: ______________ Unknown
YEAST IDENTIFICATION
7) Does this laboratory offer yeast identification (either onsite or sent to another laboratory)?
Yes
No (-------- If No, SKIP TO QUESTION 18 --------)
Unknown (is there another laboratory staff member who can assist with the questionnaire?)
8) Where is yeast identification done? (check the most applicable)
On-site, in the laboratory
Sent to commercial lab
Sent to affiliated hospital lab
Sent to other local/regional, non-affiliated reference or public health laboratory
Other ______________________________
Unknown

Answer the following questions for the lab selected in question 8.
9) How does this lab identify yeast? (check all that apply)
MALDI-TOF Bruker (Biotyper)
MALDI-TOF bioMerieux (VITEK MS)
VITEK 2
API 20C
DNA sequencing
PNA-FISH
BactiCard Candida

BD Phoenix
MicroScan
RapID Plus
Other (specify) ______________________
Unknown

10) Does this laboratory routinely use chromogenic agarfor the identification or differentiation of
Candida isolates?
Yes
No
Unknown
11) Species-level identification is performed for Candida spp. isolated from which of the
following?
a. Blood isolates

2023

Page 1 of 4

Lab ID No. [][][][][][]
Yes, with clinician order

Yes, always

b. Other normally sterile body site isolates
Yes, always
Yes, with clinician order
c. Abdominal isolates
Yes, always
Yes, with clinician order

No

Unknown

No

Unknown

No

Unknown

d. Respiratory isolates
Yes,always

Yes, with clinician order

No

Unknown

e. Urine isolates
Yes, always

Yes, with clinician order

No

Unknown

Yes, with clinician order

No

Unknown

f.

Other (specify) ____________________
Yes, always

12) How does this laboratory meet proficiency testing requirements for yeast identification?
Commercial provider (specify) _________________
Internal alternate assessments (specify) __________________
13) Does this laboratory employ culture-independent diagnostic tests (CIDTs) to identify Candida from blood
specimens?
Yes (go to Q14)

No (go to Q17)

Unknown

14) Does this laboratory employ the T2Candida Panel to identify Candida from blood specimens?
Yes (go to Q14a)
Unknown
No (go to Q15)
a. If Yes, when did this lab first start using T2Candida Panel? Date (mm/dd/yyyy): ____/____/________
b. If Yes and you get a positive result on T2Candida Panel, does this lab culture the blood to obtain
an isolate?
No
Yes, always
Unknown
Yes, with a clinical order
15) Does this laboratory employ the BioFire (FilmArray) to identify Candida from blood culture?
Unknown
Yes (go to Q15a)
No (go to Q16)
a. If Yes, when did this lab first start using BioFire? Date (mm/dd/yyyy): ____/____/________
b. If Yes and you get a positive result on BioFire, does this lab culture the blood to obtain an isolate i?
Yes, always
Yes, with a clinical order

No
Unknown

16) Does this laboratory employ any other CIDTs to identify Candida from blood specimens?
Yes (specify) ______________________
No
Unknown
17) If No for Question 13, does this laboratory have plans to employ culture-independent diagnostics for Candida
identification in the near future (e.g., T2Candida Panel, BioFire)?
Yes (specify) ___________________
Unknown
No
Not applicable
ANTIFUNGAL SUSCEPTIBILITY TESTING
18) Does this laboratory offer any antifungal susceptibility testing for Candida (either onsite or sent to another
laboratory)?

2023

Page 2 of 4

Lab ID No. [][][][][][]
Yes
No (-------- If No, QUESTIONNAIRE COMPLETE --------)
Unknown (is there another laboratory staff member who can assist with the questionnaire?)
19) Where is antifungal susceptibility testing (AFST) done? (check the most applicable)
On-site, in the laboratory (go to Q20)
Sent to commercial lab (-------- If not an on-site laboratory, QUESTIONNAIRE COMPLETE --------)
Sent to affiliated hospital lab
Sent to other local/regional, non-affiliated reference or public health laboratory
Other ______________________________
Unknown

Answer the following questions for the lab selected in question 19.
20) Is antifungal susceptibility testing available for any of the following antifungal drugs (check all that apply):
Fluconazole
Caspofungin
Voriconazole
Amphotericin B
Itraconazole
Flucytosine
Posaconazole
Other (specify) __________________
Micafungin
Unknown
Anidulafungin
21) What methods are used for AFST, excluding Amphotericin B? (check all that apply)
Vitek (bioMerieux)
Broth microdilution with laboratory developed
Other ______________________________
plates
YeastOne (Thermo Scientific™
Unknown
Sensititre™) Gradient diffusion (E test)
22) What methods are used for AFST of Amphotericin B? (check all that apply)
Broth microdilution with

Vitek (bioMerieux)

laboratory developed plates

Other ______________________________

YeastOne (Thermo Scientific™ Sensititre™)
Gradient diffusion (E test)

Unknown

23) How does this laboratory meet proficiency testing requirements for antifungal susceptibility testing, if
performed?
Commercial provider (specify) _________________
Internal alternate assessments (specify) __________________
24) How are results of AFST reported when breakpoints are available? (select one)
Categorical interpretation only (susceptible,
Both--categorical interpretation PLUS MIC
resistant, etc.)
Unknown
MIC only
25) How are results of AFST reported when breakpoints aren’t available? (select one)
MIC only

2023

Epidemiological cutoff values (ECVs)

Unknown

Page 3 of 4

Lab ID No. [][][][][][]

26) For what type of Candida isolates is antifungal susceptibility testing (AFST) performed
automatically? (check all that apply)
No AFST performed automatically (requires
Blood isolates
order from a clinician)
Other normally sterile body site isolates
Unknown
Other (specify) ______________________
27) When is AFST performed for the following Candida spp.?
a. C. albicans
Performed automatically(Go to 27ai)
Performed with a clinician’s order (Go to 27ai)
Not performed
i.

Drugs for which AFST is performed on C. albicans (check all that apply):
Fluconazole
Micafungin
Other
Anidulafungin
Voriconazole
Unknown
Caspofungin
Amphotericin B

b. C. glabrata
Performed automatically(Go to 27bi)
Performed with a clinician’s order (Go to 27bi)
Not performed
i.

Drugs for which AFST is performed on C. glabrata (check all that apply):
Micafungin
Fluconazole
Other
Anidulafungin
Voriconazole
Unknown
Caspofungin
Amphotericin B

c. C. parapsilosis
Performed automatically(Go to 27ci)
Performed with a clinician’s order (Go to 27ci)
Not performed
i.

Drugs for which AFST is performed on C. parapsilosis (check all that apply):
Micafungin
Fluconazole
Other
Anidulafungin
Voriconazole
Unknown
Caspofungin
Amphotericin B

d. Other Candida spp.
Performed automatically(Go to 27di)
Performed with a clinician’s order (Go to 27di)
Not performed
i.

28)

Drugs for which AFST is performed on other Candida spp. (check all that apply):
Micafungin
Fluconazole
Other
Anidulafungin
Voriconazole
Unknown
Caspofungin
Amphotericin B

Is this laboratory tracking susceptibility trends for Candida spp. isolates tested in your lab?
Yes

No

Unknown

------------------------------------------------ END OF QUESTIONNAIRE ------------------------------------------------

2023

Page 4 of 4


File Typeapplication/pdf
AuthorAngela Ahlquist
File Modified2023-02-28
File Created2022-10-27

© 2024 OMB.report | Privacy Policy